Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2005-01-07
2010-11-02
Cheu, Jacob (Department: 1641)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S007200, C435S007900, C435S007920
Reexamination Certificate
active
07824864
ABSTRACT:
The invention is a method and assay for detecting human squalene antibodies in sera or plasma using a blocking agent of −0.5% casein in a phosphate buffered saline (PBS) solution.
REFERENCES:
patent: 5210039 (1993-05-01), Cummins et al.
patent: 5294537 (1994-03-01), Batt
patent: 5419904 (1995-05-01), Irie
patent: 5419921 (1995-05-01), Molacek et al.
patent: 5709879 (1998-01-01), Barchfeld et al.
patent: 6166050 (2000-12-01), Lombardo et al.
patent: 6191108 (2001-02-01), Rodkey et al.
patent: 6214566 (2001-04-01), Asa et al.
patent: WO 95/00146 (1995-01-01), None
patent: WO 98/20137 (1998-05-01), None
patent: WO 01/87302 (2001-11-01), None
Harlow et al. “Antibodies a Laboratory Manual,” Cold Spring Harbor, NY, Cold Spring Harbor Laboratory Press, 1988, p. 141-155.1.
Applicant's filed affidavit & declaration in parent case (U.S. Appl. No. 09/859,389).
Alving, C.R. et al., “Preparation and Use of Liposomes in Immunological Studies”. In: G. Gregoriadis (Ed.) Liposome Technology, vol. 3 (Second Ed.), CRC Press, Inc. Boca Raton, p. 317-343, year 1993.
Mayes, P.A., “Cholesterol Synthesis, Transport, & Excretion”,Harper's Biochemistry, 24thEdition, Appleton & Lang, Stamford, 1996, p. 271-283.
Schuster, B. et al., “Production of Antibodies Against Phosphocholine, Phosphatidylcholine, Sphingomyelin, and Lipid A by Injection of Liposomes Containing Lipid A”, J. Immunol., 1979, vol. 122, No. 3, pp. 900-905.
Stollar, B.D. et al., “Cross-Reactions of Nucleic Acids With Monoclonal Antibodies to Phosphatidylinositol Phosphate and Cholesterol”, Mol. Immunol., 1989, vol. 26, No. 1, pp. 73-79.
Swartz, Jr. G.M. et al., “Antibodies to Cholesterol”, Proc. Natl. Acad. Sci. U.S.A., 1988, vol. 85, No. 6, pp. 1902-1906.
Wassef, N.M. et al, “Phosphate Binding Specificities of Monoclonal Antibodies Against Phosphoinositides in Liposomes”, 1984, vol. 21, No. 10, pp. 863-868, Book Molecular Immunology.
Phillps, Christoper J., et al., “Antibodies to squalene in US Navy Persian Gulf War veterans with chronic multisympton illness,” Vaccine, 2009, p. 391-3926, vol. 27.
Blanchard, Melvin S., et al., “Chronic Multisympton Illness Complex in Gulf War I Veterans 10 Years Later,” American Journal of Epidemiology, 2006, p. 66-75, vol. 163, No. 1.
Bonhoeffer, Jan, et al., “Adverse events following immunization: perception and evidence,” Curr Opin Infect Dis, 2007, p. 237-246, vol. 20.
Del Giudice, Giuseppe, et al., “Vaccines with the MF59 Adjuvant Do Not Stimulate Antibody Responses against Squalene,” Olin. Vaccine Immunol., Sep. 2006, p. 1010-1013, vol. 13, No. 9.
Diaz-Torne, C., et al., “Abesence of Histologic Evidence of Synovitis in Patients With Gulf War Veterans' Illness With Joint Pain,” Arthritis & Rheumatism, Oct. 15, 2007, p. 1316-1323, vol. 57, No. 7.
Ferguson, Eamonn, et al., “Theoretical accounts of Gulf War Syndrome: From environmental toxins to psychoneuroimmunology and neurdegeneration,” Behavioural Neurology, 2001/2002, p. 133-147, vol. 13.
Fraser, Claire M., “A Genomics-Based Approach to Biodefence Preparedness,” Nature Reviews, Jan. 2004, p. 23-33, vol. 5.
Fukasawa, Lucila O., “Adjuvant can improve protection induced by OMV vaccine against Neisseria meningitidis serogroups B/C in neonatal mice,” FEMS Immunology and Medical Microbiology, 2004, p. 205-210, vol. 41.
Hannan, K. L., et al., et al., “Activation of the coagulation system in Gulf War Illness: a potential pathophysiologic link with chronic fatigue syndrome A laboratory approach to diagnosis,” Blood Coagulation and Fibrinolysis, 2000, p. 673-678, vol. 11, No. 7.
Holm, Barbro C. et al., “Rats made congenic for Oia3 on chromosome 10 become susceptible to squalene-induced arthritis,” Human Molecular Genetics, 2001, p. 565-575, vol. 10, No. 6.
Hunt, Stephen C., et al., “Re: Chronic Multisympton Illness Complex in Gulf War I Veterans 10 Years Later,” Am J Epidemiol, 2006, p. 706-710, vol. 164.
Kuroda, Yoshiki, et al., “Autoimmunity induced by adjuvant hydrocarbon oil components of vaccine,” Biomedicine & Pharmacotheraphy, 2004, p. 325-337, vol. 58.
Little, Stephen F., Anthrax Vaccines A Development Update, Biodrugs, 2005, p. 233-245, vol. 19, No. 4.
Liu, Xiuping, et al., “The PorB porin from commensal Neisseria lactamica induces Th1 and Th2 immune responses to ovalbumin in mice and is a potential immune adjuvant,” Vaccine, 2008, p. 786-796, vol. 26.
O'Bryan, Thomas A., MD, et al., “Human Leukocyte Antigens in Gulf War Veterans with Chronic Unexplained Multiple Symptoms,” Military Medicine, 2003, p. 1015-1018, vol. 168, No. 12.
Petrik, Michael, S., et al., “Aluminum Adjuvant Linked to Gulf War Illness Induces Motor Neuron Death in Mice,” NeuroMolecular Medicine, 2007, p. 83-100, vol. 9.
Richardson, Ralph D., et al., “Are Veterans Seeking Veterans Affairs' Primary Care as Healthy as Those Seeking Department of Defense Primary Care? A Look at Gulf War Veterans' Symptoms and Functional Status,” Psychosomatic Medicine, 2002, p. 676-683, vol. 64.
Riedmann, Eva M., et al. “Bacterial ghosts as adjuvant particles,” Expert Rev. Vaccines, 2007, p. 241-253, vol. 6. No. 2.
Schultze, Viola, et al., “Safety of MF59™ adjuvant,” Vaccine, 2008, p. 3209-3222, vol. 26.
Smith, Tyler C., MS, et al., “The Postwar Hospitalization Experience of Gulf War Veterans Participating in U.S. Health Registries,” J Occup Environ Med., 2004, p. 386-397, vol. 2004, No. 46.
Spanggord, Ronald J., et al., “Development and application of an analytical method for the determination of squalene in formulations of anthrax vaccine adsorbed,” J. Pharm. Biomed. Anal. 2002, p. 183-93, vol. 29.
Staines, Donald, R., “Is osteoporosis linked to vaccinaitons and Gulf War Syndrome,” Medical Hypotheses, 2004, p. 670-673, vol. 62.
Vasudev, Monica, MD, et al., “New-onset rheumatoid arthritis after anthrax vaccination,” Ann Allergy Asthma Immunol., 2006, p. 110-112, vol. 97.
Wells, Timothy Steven, et al., “Military Hospitalizations Among Deployed US Service Members Following Anthrax Vaccination, 1998-2001,” Human Vaccines, Mar./Apr. 2006, p. 54-59, vol. 2, No. 2.
“Annual Review of Cosmetic Ingredient Safety Assessments—2001/2002,” International Journal of Toxicology, 2003, p. 1-35, vol. 22(Suppl. 1).
Fung et al., “3, 4-dicarboxylic Acid (A-87049): A Novel Potent Squalene Synthase Inhibitor”, Journal of Medicinal Chemistry, 1997, vol. 40, No. 14, pp. 2123-2125.
Hanley et al., “Solubilization, Partial Purification, and Immunodetection of Squalene Synthetase From Tobacco Cell Suspension Cultures”, Plant Physiology, 1992, vol. 98, No. 1, pp. 215-220.
Ryder, N.S. et al., “Interaction of Terbinafine with Human Serum and Serum Proteins”, Journal of Medical and Veterinary Mycology, 1992, vol. 30, pp. 451-460.
Aggarwal, B.B. et al., “Human Lymphotoxin: Production by a Lymphoblastoid Cell Line, Purification, and Initial Characterization”, J. Biol. Chem., 1984, vol. 259, No. 1, pp. 686-691.
Alving, C.R., “Natural Antibodies Against Phospholipids and Liposomes in Humans”, Biochem. Soc. Trans., 1984, vol. 12, No. 2, pp. 342-344.
Alving, C.R. et al., Letters to the Editor, Exp. Mol. Pathol., 2000, vol. 68, pp. 196-198.
Alving, C.R. et al., “Naturally Occurring Antibodies to Cholesterol: A New Theory of LDL Cholesterol Metabolism”, Immunol. Today, 1999, vol. 20, No. 8, pp. 362-366.
Alving, C.R. et al., “Antibodies to Cholesterol, Cholesterol Conjugates, and Liposomes: Implications for Atherosclerosis and Autoimmunity”, Crit. Rev. Immunol., 1991, vol. 10, No. 5, pp. 441-453.
Alving et al., “Immunization with Cholesterol-Rich Liposomes Induces An
Alving Carl R
Matyas Gary R
Rao Mangala
Wassef Nabila M
Arwine Elizabeth
Cheu Jacob
The United States of America as represented by the Secretary of
LandOfFree
Detection of human antibodies to squalene in serum does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Detection of human antibodies to squalene in serum, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Detection of human antibodies to squalene in serum will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4180429